Baseline serum autoantibodies for predicting recurrence and toxicity for immune checkpoint blockade in cancer patients
OwnerIman Osman, Judy Zhong +1inventors
InventorsIman Osman, Judy Zhong, Paul Johannet
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods for determining baseline serum autoantibodies (autoAbs) for use in patient selection and for treatment with immune checkpoint blockade agents to promote avoidance of development of severe immune related adverse events (IRAEs). The treatments include administering anti-cancer agents that are not predicted to cause toxicity to selected patients, and administering agents to reduce predicted toxicity in selected patients.
Claims13
A method for predicting disease recurrence and toxicity for immune checkpoint inhibitor therapy in an individual, the method comprising determining an amount of a plurality of baseline autoantibodies (autoAbs) from a biological sample obtained from the individual, and comparing the amount of baseline autoAbs from the biological sample to a reference, wherein determining a difference between the baseline autoAbs from the biological sample to the reference provides an indication of whether or not the individual will have disease recurrence and toxicity in response to immune checkpoint inhibitor therapy that may be administered to the individual subsequent to obtaining the biological sample.
A substrate comprising a plurality of proteins from Table X, wherein each protein in the plurality of proteins is reversibly or irreversibly attached to the substrate.
Dependencies are inferred from the claim text.